Skip to content

Study · Randomized controlled trial · 2010

4 results

Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics.

Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, Crawford ED, Moul J, Jensen JK, Kold Olesen T, Persson BE

European urology20 Nov 2009Cited by 100 (Europe PMC)

PMID19962227 (opens in a new tab)DOI10.1016/j.eururo.2009.11.029 (opens in a new tab)PepBankPUB-19962227
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In prostate cancer patients, degarelix significantly lowered the risk of PSA progression or death compared with leuprolide.

    In plain wordsIn prostate cancer patients, degarelix lowered the risk of PSA progression or death compared with leuprolide.

    Peptide
    Degarelix
    Outcome
    DecreasePSA progression or death
    Study

    n: not reported in source

    Comparator
    leuprolide
    Analysis
    Secondary
    Outcome group
    Tumor growth · Cancer
    Studied dose
    240/80 mg · 1 yearAs given in this study (human).

    Measurements

    P value
    0.05 NA
    PSA progression or death, degarelix 240/80 mg versus leuprolide 7.5 mg/mo

    Source sentences

    Summary
    Patients receiving degarelix showed a significantly lower risk of PSA progression or death compared with leuprolide (p=0.05).
    2 context sentences
    Summary · context
    Phase 3, 1-yr, multicentre, randomised, open-label trial comparing the efficacy and safety of degarelix at 240 mg for 1 mo, and then 80 mg monthly (240/80 mg); degarelix at 240 mg for 1 mo, and then 160 mg monthly; and leuprolide at 7.5 mg/mo.
    Summary · context
    The primary end point of this trial has been reported previously; the protocolled and exploratory subgroup analyses reported in this paper focus on degarelix at 240/80 mg (dose approved by the US Food and Drug Administration and the European Medicine Evaluation Association for the treatment of patie…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In prostate cancer patients, the risk of PSA progression or death was significantly higher with leuprolide than degarelix.

    In plain wordsIn prostate cancer patients, the risk of PSA progression or death was higher with leuprolide than degarelix.

    Peptide
    Leuprolide
    Outcome
    IncreasePSA progression or death
    Study

    n: not reported in source

    Comparator
    degarelix 240/80 mg
    Analysis
    Secondary
    Outcome group
    Tumor growth · Cancer
    Studied dose
    7.5 mg/mo · 1 yearAs given in this study (human).

    Measurements

    P value
    0.05 NA
    PSA progression or death, leuprolide 7.5 mg/mo versus degarelix 240/80 mg

    Source sentences

    Summary
    Patients receiving degarelix showed a significantly lower risk of PSA progression or death compared with leuprolide (p=0.05).
    2 context sentences
    Summary · context
    Phase 3, 1-yr, multicentre, randomised, open-label trial comparing the efficacy and safety of degarelix at 240 mg for 1 mo, and then 80 mg monthly (240/80 mg); degarelix at 240 mg for 1 mo, and then 160 mg monthly; and leuprolide at 7.5 mg/mo.
    Summary · context
    The primary end point of this trial has been reported previously; the protocolled and exploratory subgroup analyses reported in this paper focus on degarelix at 240/80 mg (dose approved by the US Food and Drug Administration and the European Medicine Evaluation Association for the treatment of patie…
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with PSA >20 ng/ml, degarelix significantly prolonged time to PSA recurrence compared with leuprolide.

    In plain wordsIn prostate cancer patients with high PSA, degarelix prolonged time to PSA recurrence compared with leuprolide.

    Peptide
    Degarelix
    Outcome
    IncreaseTime to PSA recurrence with high baseline PSA
    Study

    n: not reported in source

    Comparator
    leuprolide
    Outcome group
    Tumor growth · Cancer
    Studied dose
    240/80 mg · 1 yearAs given in this study (human).

    Measurements

    P value
    0.04 NA
    baseline PSA >20 ng/ml, time to PSA recurrence, degarelix versus leuprolide

    Source sentences

    Summary
    Patients with PSA >20 ng/ml had a significantly longer time to PSA recurrence with degarelix (p=0.04).
    2 context sentences
    Summary · context
    Phase 3, 1-yr, multicentre, randomised, open-label trial comparing the efficacy and safety of degarelix at 240 mg for 1 mo, and then 80 mg monthly (240/80 mg); degarelix at 240 mg for 1 mo, and then 160 mg monthly; and leuprolide at 7.5 mg/mo.
    Summary · context
    The primary end point of this trial has been reported previously; the protocolled and exploratory subgroup analyses reported in this paper focus on degarelix at 240/80 mg (dose approved by the US Food and Drug Administration and the European Medicine Evaluation Association for the treatment of patie…
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with PSA >20 ng/ml, time to PSA recurrence was shorter with leuprolide than degarelix.

    In plain wordsIn prostate cancer patients with high PSA, time to PSA recurrence was shorter with leuprolide than degarelix.

    Peptide
    Leuprolide
    Outcome
    DecreaseTime to PSA recurrence with high baseline PSA
    Study

    n: not reported in source

    Comparator
    degarelix
    Outcome group
    Tumor growth · Cancer
    Studied dose
    7.5 mg/mo · 1 yearAs given in this study (human).

    Measurements

    P value
    0.04 NA
    baseline PSA >20 ng/ml, time to PSA recurrence, leuprolide versus degarelix

    Source sentences

    Summary
    Patients with PSA >20 ng/ml had a significantly longer time to PSA recurrence with degarelix (p=0.04).
    2 context sentences
    Summary · context
    Phase 3, 1-yr, multicentre, randomised, open-label trial comparing the efficacy and safety of degarelix at 240 mg for 1 mo, and then 80 mg monthly (240/80 mg); degarelix at 240 mg for 1 mo, and then 160 mg monthly; and leuprolide at 7.5 mg/mo.
    Summary · context
    The primary end point of this trial has been reported previously; the protocolled and exploratory subgroup analyses reported in this paper focus on degarelix at 240/80 mg (dose approved by the US Food and Drug Administration and the European Medicine Evaluation Association for the treatment of patie…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.